MiNK Therapeutics
Tracked across 31 events · 393 articles · First seen Oct 06, 2025 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: MiNK Therapeutics is the defendant in a securities fraud class action lawsuit, accused of making materially false and misleading statements regarding its DCCR clinical trial program, which led to a significant stock price decline.
Apr 01, 2026 · 6 articles
Business
Impact: MiNK Therapeutics is being acquired by Neurocrine Biosciences for $2.9 billion, representing a significant premium for its shareholders. Its product, VYKAT XR, is a key asset in this transaction.
Apr 06, 2026 · 6 articles
Tech
Impact: MiNK Therapeutics announced new clinical and translational data for its Agent 797 therapy, which could significantly boost its market position and future revenue streams.
May 20, 2026 · 9 articles
Tech
Impact: MiNK Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial for agenT-797, a significant step in developing a new therapy for acute lung injury and critical illness. This advancement could positively impact its stock price and market position.
May 28, 2026 · 6 articles
Regulatory
Impact: MiNK Therapeutics is facing a securities fraud investigation by Pomerantz LLP due to significant stock price drops following the voluntary pause and subsequent clinical hold on its HERO trial for ARD-101. This event negatively impacts its reputation and financial standing.
May 21, 2026 · 6 articles
Business
Impact: MiNK Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA to the United States — Food and Drug Administration (FDA) for the treatment of neovascular age-related macular degeneration (nAMD), which is a significant step towards potential FDA approval and commercialization in the United States.
May 26, 2026 · 7 articles
Business
Impact: MiNK Therapeutics received over £2.2M in grants, validating its gene-control technology and enabling expansion into new therapeutic areas and platform development. This funding supports its pipeline, including programs for solid tumors and non-oncology indications.
Jun 01, 2026 · 6 articles
Business
Impact: MiNK Therapeutics is holding its Annual Shareholders Meeting, which is a routine corporate governance event for the company.
Jun 03, 2026 · 6 articles
Business
Impact: MiNK Therapeutics is participating in a major healthcare conference, which provides an opportunity to present its product candidate, lorundrostat, and potentially attract investor interest, positively impacting its visibility and stock.
Jun 08, 2026 · 7 articles
Business
Impact: MiNK Therapeutics is exploring strategic alternatives to maximize stakeholder value, including potential transactions for its gene therapy programs and technology platforms. This could lead to partnerships, acquisitions, or other deals that impact its financial future and stock price.
Jun 08, 2026 · 7 articles
Business
Impact: Whitehawk gains access to bispecific antibodies to combine with its ADC platform, aiming to deliver new INDs within 12-24 months.
Jul 07, 2026 · 7 articles
Business
Impact: MiNK Therapeutics is the company whose abstract was accepted for an oral presentation at ESMO, a positive development for its pipeline.
Jul 17, 2026 · 7 articles
Business
Impact: MiNK Therapeutics is the licensor, granting exclusive rights to senaparib. The deal provides substantial financial upside and expands its global footprint, positively impacting its valuation.
Jul 31, 2026 · 8 articles
Business
Impact: MiNK Therapeutics is the entity undergoing the rebrand to Cerenome, Inc. The change to a new name and ticker symbol reflects its strategic shift toward an integrated CNS oncology platform, which may positively influence investor perception.
Jul 31, 2026 · 6 articles
Business
Impact: MiNK Therapeutics is the company announcing its Q2 2026 financial results and clinical update. The event is a routine corporate communication, with potential positive sentiment if the clinical data for Agent 797 is favorable.
Aug 06, 2026 · 6 articles
Tech
Impact: MiNK Therapeutics is the developer of Agent 797 and presented the positive Phase 2 data, which could enhance its pipeline value and stock performance.
Aug 06, 2026 · 6 articles
Business
MiNK Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for retinal diseases, announced the pricing of an underwritten public offering of 55,555,556 shares of common…
Impact: MiNK Therapeutics is the issuer of the offering, raising approximately $55 million to fund the U.S. commercial launch of LYTENAVA and for working capital. The offering provides necessary capital but may dilute existing shareholders.
Aug 12, 2026 · 7 articles
Regulatory
MiNK Therapeutics, Inc. (NASDAQ: AARD), a clinical-stage biopharmaceutical company developing ARD-101 for Prader-Willi Syndrome, faces a securities class action lawsuit. The suit alleges that the company and certain officers made materially false and misleading statements…
Impact: MiNK Therapeutics is the defendant in the securities class action. The FDA clinical hold on ARD-101 and the alleged misrepresentations have caused a dramatic stock price decline and significant legal and financial exposure.
Aug 14, 2026 · 23 articles
Business
Impact: As the parent company of C2N Diagnostics, MiNK Therapeutics benefits from the CAP accreditation, which enhances the credibility and commercial prospects of its CNS cancer diagnostic and radiopharmaceutical pipeline.
Jun 04, 2026 · 7 articles
Tech
Impact: MiNK Therapeutics, a subsidiary of NRx Pharmaceuticals, has transitioned from system deployment to active patient care using the Zeta TMS Navigation System, offering advanced psychiatric and neurological care.
Jun 25, 2026 · 6 articles
Business
Impact: Lost arbitration; no monetary damages awarded; PM647 excluded from its licensed field.
Jul 08, 2026 · 6 articles
Tech
Impact: MiNK Therapeutics, a subsidiary of Bayer, is exploring approaches related to regulatory T cells, contributing to the development of new treatments.
Oct 06, 2025 · 6 articles
Tech
Impact: MiNK Therapeutics, through its Research Scientist Live (band), provided positive feedback on the performance of the new GTxResolve Lipid RP Columns.
Jun 08, 2026 · 10 articles
Business
Impact: MiNK Therapeutics is a neuroscience-focused research organization that Wellgistics is considering acquiring through an all-stock transaction, suggesting further diversification for Wellgistics.
May 20, 2026 · 9 articles
+ 1 more events
View on Dashboard
100
MiNK Therapeutics announced meetingOutlook Therapeutics $55M...
92
Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit MiNK TherapeuticsAardvark Therapeutics...
92
United States — Food and Drug Administration placed clinical hold MiNK TherapeuticsAardvark Therapeutics...
90
MiNK Therapeutics paused HERO trialAardvark Therapeutics...
82
Hagens Berman filed lawsuit MiNK TherapeuticsAardvark Therapeutics...
70
Robbins LLP filed class action MiNK TherapeuticsAardvark Therapeutics...
40
MiNK Therapeutics granted underwriter optionOutlook Therapeutics $55M...
20
MiNK Therapeutics filed shelf registration United States — United States Securities and Exchange CommissionOutlook Therapeutics $55M...
ERGEN INTELLIGENCE
Track MiNK Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard